acemannan has been researched along with Diabetes Mellitus, Type 2 in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahmed, MM; Al-Abbasi, FA; Alghamdi, AM; Altayb, HN; Alzarea, SI; Gupta, G; Kazmi, I; Nadeem, MS; Omer, AB; Sayyed, N | 1 |
1 other study(ies) available for acemannan and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Acemannan ameliorates STZ-activated diabetes by attenuating high glucose via inhibiting inflammatory cytokines and apoptosis pathway.
Topics: Animals; Apoptosis; Cytokines; Diabetes Mellitus, Type 2; Glucose; Humans; Molecular Docking Simulation; Oxidative Stress; Rats; Streptozocin | 2023 |